WallStreetZenWallStreetZen

NASDAQ: NTLA
Intellia Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for NTLA

Based on 8 analysts offering 12 month price targets for Intellia Therapeutics Inc

Min Forecast
$8.00-24.17%
Avg Forecast
$21.88+107.35%
Max Forecast
$49.00+364.45%

Should I buy or sell NTLA stock?

Based on 8 analysts offering ratings for Intellia Therapeutics Inc.

Hold
Strong Buy
1 analysts 12.5%
Buy
3 analysts 37.5%
Hold
2 analysts 25%
Sell
1 analysts 12.5%
Strong Sell
1 analysts 12.5%
Although NTLA's forecast from analysts indicates a "Hold", our proven Zen Rating quant model rates NTLA as a "Strong Sell". Stocks with a Zen Rating of Strong Sell have had an average return of -12.86% per year. Learn More

Be the first to know when Wall Street analysts revise their NTLA stock forecasts and price targets.

NTLA stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-10-06
lockedlocked$00.00+00.00%2026-09-09
lockedlocked$00.00+00.00%2026-09-09
lockedlocked$00.00+00.00%2026-09-09
lockedlocked$00.00+00.00%2026-08-07
Wolfe Research
Top 9%
92
SellDowngrades$9.00-14.69%2026-07-16
Canaccord Genuity
Top 8%
93
Strong BuyMaintains$49.00+364.45%2026-06-16
Bernstein
Top 40%
61
HoldMaintains$17.00+61.14%2026-05-13

1 of 1

Forecast return on equity

Is NTLA forecast to generate an efficient return?

Company
95.17%
Industry
19.54%
Market
161.2%
NTLA's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is NTLA forecast to generate an efficient return on assets?

Company
64.65%
Industry
19.93%
NTLA is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

NTLA earnings per share forecast

What is NTLA's earnings per share in the next 3 years based on estimates from 20 analysts?

Avg 1 year Forecast
-$3.26
Avg 2 year Forecast
-$2.86
Avg 3 year Forecast
-$2.33

NTLA revenue forecast

What is NTLA's revenue in the next 3 years based on estimates from 20 analysts?

Avg 1 year Forecast
$47.8M-9.62%
Avg 2 year Forecast
$81.6M+54.32%
Avg 3 year Forecast
$201.8M+281.59%
NTLA's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

NTLA revenue growth forecast

How is NTLA forecast to perform vs Biotechnology companies and vs the US market?

Company
51.67%
Industry
31.51%
Market
12.32%
NTLA's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
NTLA's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

NTLA vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
NTLA$10.55$21.88+107.35%Hold
NVAX$8.76$14.33+63.62%Buy
NUVB$4.06$13.86+241.31%Strong Buy
RAPP$25.85$65.25+152.42%Strong Buy
ANAB$47.77$76.17+59.45%Strong Buy
View Top Biotech Stocks

Intellia Therapeutics Stock Forecast FAQ

Is Intellia Therapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 8 Wall Street analysts covering (NASDAQ: NTLA) stock is to Hold NTLA stock.

Out of 8 analysts, 1 (12.5%) are recommending NTLA as a Strong Buy, 3 (37.5%) are recommending NTLA as a Buy, 2 (25%) are recommending NTLA as a Hold, 1 (12.5%) are recommending NTLA as a Sell, and 1 (12.5%) are recommending NTLA as a Strong Sell.

If you're new to stock investing, here's how to buy Intellia Therapeutics stock.

What is NTLA's earnings growth forecast for 2026-2028?

(NASDAQ: NTLA) Intellia Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.85%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.79%.

Intellia Therapeutics's earnings in 2026 is -$426,136,000.On average, 20 Wall Street analysts forecast NTLA's earnings for 2026 to be -$457,358,211, with the lowest NTLA earnings forecast at -$470,425,589, and the highest NTLA earnings forecast at -$418,549,083. On average, 20 Wall Street analysts forecast NTLA's earnings for 2027 to be -$401,411,308, with the lowest NTLA earnings forecast at -$500,686,884, and the highest NTLA earnings forecast at -$302,711,203.

In 2028, NTLA is forecast to generate -$327,217,799 in earnings, with the lowest earnings forecast at -$447,041,861 and the highest earnings forecast at -$154,745,259.

What is NTLA's revenue growth forecast for 2026-2028?

(NASDAQ: NTLA) Intellia Therapeutics's forecast annual revenue growth rate of 51.67% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 31.51%, and it is also forecast to beat the US market's average forecast revenue growth rate of 12.32%.

Intellia Therapeutics's revenue in 2026 is $52,887,000.On average, 20 Wall Street analysts forecast NTLA's revenue for 2026 to be $6,709,277,232, with the lowest NTLA revenue forecast at $5,071,574,114, and the highest NTLA revenue forecast at $14,737,643,760. On average, 20 Wall Street analysts forecast NTLA's revenue for 2027 to be $11,455,640,674, with the lowest NTLA revenue forecast at $3,140,240,989, and the highest NTLA revenue forecast at $26,407,050,448.

In 2028, NTLA is forecast to generate $28,325,751,307 in revenue, with the lowest revenue forecast at $6,189,810,379 and the highest revenue forecast at $50,447,656,383.

What is NTLA's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: NTLA) forecast ROA is 64.65%, which is higher than the forecast US Biotechnology industry average of 19.93%.

What is NTLA's Price Target?

According to 8 Wall Street analysts that have issued a 1 year NTLA price target, the average NTLA price target is $21.88, with the highest NTLA stock price forecast at $49.00 and the lowest NTLA stock price forecast at $8.00.

On average, Wall Street analysts predict that Intellia Therapeutics's share price could reach $21.88 by Oct 6, 2027. The average Intellia Therapeutics stock price prediction forecasts a potential upside of 107.35% from the current NTLA share price of $10.55.

What is NTLA's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: NTLA) Intellia Therapeutics's current Earnings Per Share (EPS) is -$3.34. On average, analysts forecast that NTLA's EPS will be -$3.26 for 2026, with the lowest EPS forecast at -$3.35, and the highest EPS forecast at -$2.98. On average, analysts forecast that NTLA's EPS will be -$2.86 for 2027, with the lowest EPS forecast at -$3.57, and the highest EPS forecast at -$2.16. In 2028, NTLA's EPS is forecast to hit -$2.33 (min: -$3.19, max: -$1.10).

What is NTLA's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: NTLA) forecast ROE is 95.17%, which is considered strong.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.